The Risks and Benefits of Therapy with Aldosterone Receptor Antagonist Therapy

Sica, Domenic A.
January 2007
Current Drug Safety;Jan2007, Vol. 2 Issue 1, p71
Academic Journal
Spironolacotone and eplerenone are mineralocorticoid-blocking agents. These compounds block both the epithelial and non-epithelial actions of aldosterone with the latter assuming increasing clinical importance. Spironolactone and eplerenone both effectively reduce blood pressure either as mono- or add-on therapy; moreover, they each offer survival benefits in diverse circumstances of heart failure and the potential for renal protection in proteinuric chronic kidney disease. However, as the use of mineralocorticoid-blocking agents has increased the hazards inherent to use of such drugs has become more apparent. Whereas; the endocrine side-effects of spironolactone are in most cases little more than a cosmetic annoyance the potassium-sparing effects of both spironolactone and eplerenone can prove fatal if sufficient degrees of hyperkalemia develop. However, for most patients the risk of developing hyperkalemia in and of itself should not discourage the sensible clinician from bringing these compounds into play. Hyperkalemia should always be considered as a possibility in any patient receiving one or the other of these medications. As such, steps should be taken to lessen the likelihood of its occurring if therapy is being contemplated with agents in this class.


Related Articles

  • Aldosterone Receptor Antagonists for Hypertension: What Do They Offer? Liew, Danny; Krum, Henry // Drugs;2003, Vol. 63 Issue 19, p1963 

    Aldosterone is an important and independent target for therapeutic intervention in hypertension and hypertension-related diseases. Its actions, once thought to be limited to the distal convoluted tubule of the kidney, are now recognised to be wide-ranging, including interactions with...

  • Early Spironolactone Treatment Attenuates Heart Failure Development by Improving Myocardial Function and Reducing Fibrosis in Spontaneously Hypertensive Rats. Cezar, Marcelo D.M.; Damatto, Ricardo L.; Pagan, Luana U.; Lima, aline R.R.; Martinez, Paula F.; Bonomo, Camila; Rosa, Camila M.; Campos, Dijon H.S.; Cicogna, antonio C.; Gomes, Mariana J.; Oliveira-Jr, Silvio a.; Blotta, Daniella a.; Okoshi, Marina P.; Okoshi, Katashi // Cellular Physiology & Biochemistry (Karger AG);Jul2015, Vol. 36 Issue 4, p1453 

    Background: We evaluated the role of the aldosterone blocker spironolactone in attenuating long-term pressure overload-induced cardiac remodeling and heart failure (HF) in spontaneously hypertensive rats (SHR). Methods and Results: Thirteen month-old male SHR were assigned to control (SHR-C,...

  • Aldosterone Antagonism Fails to Attenuate Age-Associated Left Ventricular Fibrosis. Hyun Seok Hwang; Cirrincione, Georgina; Thomas, D. Paul; McCormick, Richard J.; Boluyt, Marvin O. // Journals of Gerontology Series A: Biological Sciences & Medical ;Apr2007, Vol. 62 Issue 4, p382 

    Collagen accumulates disproportionately in cardiac remodeling induced by hypertension and associated with advancing age. Spironolactone (Spiro), an aldosterone antagonist, attenuates the accumulation of collagen induced by hypertension. It was hypothesized that Spiro would attenuate the...

  • Antihypertensive and Cardiorenal Protective Effects of SM-368229, a Novel Mineralocorticoid Receptor Antagonist, in Aldosterone/Salt-Treated Rats. Nariai, Tetsuro; Fujita, Katsuya; Mori, Masaya; Katayama, Seiji; Hori, Seiji; Matsui, Kazuki // Pharmacology;2012, Vol. 89 Issue 1/2, p44 

    The purpose of this study was to evaluate the effects of SM-368229, a novel mineralocorticoid receptor (MR) antagonist, on the blood pressure and cardiorenal injury markers in aldosterone/salt-treated hypertensive rats, in comparison to those of spironolactone (SPI). Uninephrectomized rats,...

  • Aldosterone Antagonists � Last Man Standing? Armstrong, Paul W. // New England Journal of Medicine;1/6/2011, Vol. 364 Issue 1, p79 

    The author reflects on aldosterone antagonists in the treatment of heart failure. It says that in the turn of the millennium, there are four cardiac medicines developed before 1960 that survived namely aspirin, digoxin, warfarin and spironolactone. It highlights two studies whose findings have...

  • Hyperkalaemia in the age of aldosterone antagonism. Chapagain, A.; Ashman, N. // QJM: An International Journal of Medicine;Nov2012, Vol. 105 Issue 11, p1049 

    Hyperkalaemia is well recognized as a medical emergency. However, with the publication of trials showing benefit with renin-aldosterone axis suppression in heart failure, the epidemiology of patients presenting with hyperkalaemia has changed. The reported incidence of rate of serious...

  • Aldactide 50.  // Royal Society of Medicine: Medicines;2002, p42 

    The article presents information on Aldactide 50, a proprietary, prescription-only compound preparation of the aldosterone-antagonist and potassium-sparing spironolactone and the thiazide-type diuretic hydroflumethiazide. This drug can be used for heart failure treatment and is available as tablets.

  • Spironolactone.  // Reactions Weekly;3/10/2007, Issue 1142, p21 

    The article presents a case report of a man with congestive heart failure and was receiving spironolactone daily. It states that a condition called gynecomastia which is an increasing breast size in the patient during his treatment made his medication replaced by eplerenone. The author mentions...

  • Aldosterone antagonists in heart failure with reduced ejection fraction. O'Donovan, Kate // Nurse Prescribing;2015, Vol. 13 Issue 5, p242 

    Heart failure with reduced ejection fraction is associated with increased mortality, limited functional capacity and poor quality of life. The renin--angiotensin--aldosterone system (RAAS) is an essential compensatory mechanism that attempts to maintain organ perfusion. The secretion of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics